Related Experiment Video
Updated: Jun 1, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders
Olivier J Manzoni1, Antonia Manduca2, Viviana Trezza3
1INMED, INSERM, Aix-Marseille University, 13273 Marseille, France.
Abstract:
Cannabidiol (CBD), the primary non-intoxicating compound in cannabis, is currently approved for treating rare, treatment-resistant seizures. Recent preclinical research suggests that CBD's multifaceted mechanisms of action in the brain, which involve multiple molecular targets, underlie its neuroprotective, anti-inflammatory, anxiolytic, and antipsychotic effects. Clinical trials are also exploring CBD's therapeutic potential beyond its current uses. This review focuses on CBD's polypharmacological profile and discusses the latest preclinical and clinical findings regarding its efficacy in neuropsychiatric disorders. Existing evidence suggests that CBD's ability to modulate multiple signaling pathways may benefit neuropsychiatric disorders, and we propose further research areas to clarify its mechanisms, address data gaps, and refine its therapeutic indications.
Related Concept Videos
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Psychosis and Antipsychotic Drugs: Overview

